Fernand Labrie

Publications

Page 5 of 8, showing 50 records out of 362 total, starting on record 201, ending on 250

Publication Category Year
162. Labrie, F., Crawford, D.; (1995) Anti-androgens in treatment of prostate cancer. Lancet, 346: 1030-1031. Prostate Cancer 1995
161. Labrie, F., Cusan, L., Dupont, A., Gomez, J.-L., Simard, J., Luu-The, V., Pelletier, G., Labrie, C., Bélanger, A. (1996) Androgen receptor antagonists (Chapter 28), in: Adashi, E.Y., Rock, J.A. et Rosenwaks, Z., eds: Reproductive Endocrinology, Surgery and Technology, Philadelphia, Lippincott-Raven Publishers, pp 559-583. Prostate Cancer 1996
160. Labrie, F., Cusan, L., Gomez, J.-L., Bélanger, A., Candas, B. (1999) Long-term combined androgen blockade alone for localized prostate cancer. Mol. Urol., 3: 217-226. Prostate Cancer 1999
159. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Bélanger, A., Candas, B. (1996) Combination therapy in localized prostate cancer (Chapter 4), in: Schroder, F.H., ed. Recent Advances in Prostate Cancer and BPH, Parthenon Publishing, pp 31-43. Prostate Cancer 1996
158. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Bélanger, A., Candas, B. (1997) Long-term neoadjuvant and adjuvant combined androgen blockade is needed for efficacy of treatment in localized prostate cancer. Mol. Urol., 1: 253-261. Prostate Cancer 1997
157. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Candas, B. (1995) Combination of screening and preoperative endocrine therapy: the potential for an important decrease in prostate cancer mortality. J. Clin. Endocrinol. Metab., 80: 2002-2013. Prostate Cancer 1995
156. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Suburu, R., Lemay, M., Candas, B. (1995) Screening und Re-Screening des Prostatakarzinoms: Die Quebec-Studie, in Faul, P. et Altwein, J.E., eds: Screening des Prostatakarzinoms, Berlin, Springer-Verlag, pp 339-352. Prostate Cancer 1995
155. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Suburu, R., Lemay, M., Tetu, B., Fradet, Y., Bélanger, A., Candas, B. (1997) Neoadjuvant hormonal therapy: the Canadian experience. Urology, 49: 56-64. Prostate Cancer 1997
154. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Suburu, R., Lemay, M., Tetu, B., Fradet, Y., Candas, B. (1994) Downstaging of early stage prostate cancer before radical prostatectomy: the first randomized trial of neoadjuvant combination therapy with Flutamide and a luteinizing hormone-releasing hormone agonist. Urology, 44: 29-37. Prostate Cancer 1994
153. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Suburu, R., Lemay, M., Tetu, B., Fradet, Y., Candas, B. (1995) Downstaging by combination therapy with flutamide and an LHRH agonist before radical prostatectomy. Cancer Surv. 23: 149-156. Prostate Cancer 1995
152. Labrie, F., Cusan, L., Séguin, C., Bélanger, A., Pelletier, G., Reeves, J., Kelly, P.A., Lemay, A., Raynaud, J.P. (1980) Antifertility effects of LHRH agonists in the male rat and inhibition of testicular steroidogenesis in man. Int. J. Fertil., 25: 157-170. Prostate Cancer 1980
151. Labrie, F., Dupont, A., Bélanger, A. (1984) Complete androgen neutralization is most important in the treatment of prostate cancer, in: Harrap, K.R., Davis, W. et Calvert, A.H., eds: Cancer Chemotherapy and Selective Drug Development, Martinus Nijihoff Publishing, pp 475-479. Prostate Cancer 1984
150. Labrie, F., Dupont, A., Bélanger, A. (1984) Un nouveau traitement du cancer de la prostate: la suppression complète des androgènes, in: Mauvais-Jarvis, P. et Schaison, G., eds: Médecine de la reproduction masculine, Flammarion, Presses Université de Montréal, pp 367-383. Prostate Cancer 1984
149. Labrie, F., Dupont, A., Bélanger, A. (1985) Complete androgen blockade for the treatment of prostate cancer, in: DeVita, V.T., Hellman, S. et Rosenberg, S.A., eds: Important Advances in Oncology, Philadelphia, J.B. Lippincott, pp 193-217. Prostate Cancer 1985
148. Labrie, F., Dupont, A., Bélanger, A. (1986) Blocco totale degli androgeni nel trattamento del cancro della prostata. Essex Oncologia, 3-47. Prostate Cancer 1986
147. Labrie, F., Dupont, A., Bélanger, A. (1986) Combined therapy with an LHRH agonist and a pure antiandrogen in prostate cancer, in: Paulson, J.D., Negro-Vilar, A., Lucena, E. et Martini, L., eds: Andrology: Male Fertility and Sterility, New York, Academic Press, pp 39-55. Prostate Cancer 1986
146. Labrie, F., Dupont, A., Bélanger, A. (1986) LHRH analogues in prostate cancer. Lancet, Vol. I: 445-446. Prostate Cancer 1986
145. Labrie, F., Dupont, A., Bélanger, A. (1987) LHRH agonists and antiandrogens in prostate cancer, in: Catalona, W.J. et Ratliff, T.L., eds: Genitourinary Cancer, Boston, Martinus Nijhoff Publishing, pp 157-200. Prostate Cancer 1987
144. Labrie, F., Dupont, A., Bélanger, A., Cusan, L., Brochu, M., Turina, E., Pinault, S., Lacourcière, Y., Emond, J. (1989) Anti-hormone treatment in stage D2 prostate cancer patients relapsing under treatment with Flutamide and castration: addition of aminoglutethimide and low dose hydrocortisone to combination therapy. Br. J. Urol., 63: 634-638. Prostate Cancer 1989
143. Labrie, F., Dupont, A., Bélanger, A., Cusan, L., Giguère, M., Lacourcière, Y., Luthy, I., Bégin, D., Labrie, C., Simard, J., Monfette, G., Emond, J. (1987) Combination therapy in stage C and D prostatic cancer: rationale and 5-year clinical experience, in: Poste, G. et Fidler, I.J., eds: Cancer and Metastatic Reviews, Boston, Martinus Nijhoff Publishing, pp 615-636. Prostate Cancer 1987
142. Labrie, F., Dupont, A., Bélanger, A., Cusan, L., Lacourcière, Y., Monfette, G., Laberge, J.G., Emond, J., Fazekas, A.T.A., Raynaud, J.P., Husson, J.M. (1982) New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and antiandrogen. Clin. Invest. Med., 5: 267-275. Prostate Cancer 1982
141. Labrie, F., Dupont, A., Bélanger, A., Emond, J., Monfette, G. (1984) Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer. Proc. Natl. Acad. Sci. USA, 81: 3861-3863. Prostate Cancer 1984
140. Labrie, F., Dupont, A., Bélanger, A., Emond, J., Monfette, G., Luthy, I., Simard, J., Lachance, R. (1987) Flutamide in combination with castration (surgical or medical) is the standard treatment in advanced prostate cancer. J. Drug Develop., 1: 34-51. Prostate Cancer 1987
139. Labrie, F., Dupont, A., Bélanger, A., Giguère, M., Borsanyi, J.P., Bergeron, N., Lacourcière, Y., Emond, J., Monfette, G., Lachance, R. (1987) Combination therapy with Flutamide and castration in prostate cancer: four years of experience, in: D'Agata, R. et Chrousos, G.P., eds: Recent Advances in Adrenal Regulation and Function, New York, Raven Press, pp 209-221. Prostate Cancer 1987
138. Labrie, F., Dupont, A., Bélanger, A., Giguère, M., Borsanyi, J.P., Lacourcière, Y., Emond, J., Monfette, G. (1987) Combined blockade with a pure antiandrogen (Flutamide) should be used without interruption in all patients with previously untreated or treated advanved prostate cancer, in: Beaulieu, E.E., Lacobelli, S. et McGuire, W.L., eds: Endocrinology and Malignancy - Basic and Clinical Issues. Proc. First International Congress on Cancer and Hormones, London, The Parthenon Publishing Group, pp 348-360. Prostate Cancer 1987
137. Labrie, F., Dupont, A., Bélanger, A., Giguère, M., Borsanyi, J.P., Lacourcière, Y., Emond, J., Monfette, G., Lachance, R. (1987) Combination therapy with Flutamide and castration (LHRH agonist or orchiectomy): the minimal endocrine therapy in prostate cancer, in: McCann, S.M. et Weiner, R., eds: Integrative Neuroendocrinology: Molecular Cellular and Clinical Aspects, S. Karger, A.G. Basel, pp 220-234. Prostate Cancer 1987
136. Labrie, F., Dupont, A., Bélanger, A., Giguère, M., Borsanyi, J.P., Lacourcière, Y., Emond, J., Monfette, G., Lachance, R. (1987) The importance of combination therapy with Flutamide and castration (LHRH agonist or orchiectomy) in previously untreated as well as previously treated patients with advanced prostate cancer, in: Klijn, J.G.M., Paridaens, R. et Foekens, J.A., eds: Hormonal Manipulation of Cancer: Peptides growth factors and new (anti)-steroidal agents. Monograph Series of the Europea, New York, Raven Press, pp 291-300. Prostate Cancer 1987
135. Labrie, F., Dupont, A., Bélanger, A., Giguère, M., Lacourcière, Y., Emond, J., Monfette, G., Bergeron, V. (1985) Combination therapy with Flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. J. Steroid Biochem., 23: 833-841. Prostate Cancer 1985
134. Labrie, F., Dupont, A., Bélanger, A., Husson, J.M., Raynaud, J.P. (1983) Nouveau traitement antihormonal avec un antiandrogène et un agoniste de la LHRH dans le cancer de la prostate. Ann. Endocrinol. (Paris), 44: 343-344. Prostate Cancer 1983
133. Labrie, F., Dupont, A., Bélanger, A., Labrie, C., Lacourcière, Y., Emond, J., Monfette, G., Houle, J.G., Girard, J.G., Vallières, A., Bossé, C., Delisle, R. (1984) Dramatic response of prostate cancer to complete antihormonal treatment, in: Bracci, U. et Silverio, F.D., eds: Advances in Urological Oncology and Endocrinology, Rome, Acta Medica, Edizione E Congressi, pp 233-248. Prostate Cancer 1984
132. Labrie, F., Dupont, A., Bélanger, A., Labrie, C., Lacourcière, Y., Raynaud, J.P., Husson, J.M., Emond, J., Houle, J.G., Girard, J.G., Monfette, G., Paquet, J.P., Vallières, A., Bossé, C., Delisle, R. (1984) Combined antihormonal treatment in prostate cancer: a new approach using an LHRH agonist or castration and an antiandrogen, in: Bresciani, F., King, R.J.B., Lippman, M.E. et Raynaud, J.P., eds: Hormones and cancer 2: Proceedings of the Second International Congress on Hormones and Cancer, New York, Raven Press, pp 533-547. Prostate Cancer 1984
131. Labrie, F., Dupont, A., Bélanger, A., Lachance, R. (1987) Flutamide eliminates the risk of disease flare in prostate cancer patients treated with an LHRH agonist. J. Urol., 138: 804-806. Prostate Cancer 1987
130. Labrie, F., Dupont, A., Bélanger, A., Lachance, R., Giguère, M. (1985) Long-term treatment with luteinizing hormone-releasing hormone agonists and maintenance of serum testosterone to castration concentrations. Br. Med. J. (Clin. Res. Ed.), 291: 369-370. Prostate Cancer 1985
129. Labrie, F., Dupont, A., Bélanger, A., Lacourcière, Y., Emond, J., Monfette, G. (1984) Combined antiandrogen blockade in adenocarcinoma of the prostate: the first application of a successful new therapeutic principle in hormone-dependent cancer, in: Arvis, G., ed. Second International Forum on Andrology, Expansion Scientifique Française, Paris, pp 163-196. Prostate Cancer 1984
128. Labrie, F., Dupont, A., Bélanger, A., Lacourcière, Y., Emond, J., Monfette, G., Bergeron, V. (1985) Antiandrogènes et agonistes de la LHRH dans le traitement du cancer de la prostate. Médecine/Sciences, 1: 435-439. Prostate Cancer 1985
127. Labrie, F., Dupont, A., Bélanger, A., Lacourcière, Y., Giguère, M., Emond, J., Monfette, G. (1986) Traitement antiandrogénique combiné dans l'adénocarcinome de la prostate: première application d'un nouveau principe thérapeutique dans le cancer hormono-dépendant. Ann. Urol. (Paris), 20: 98-106. Prostate Cancer 1986
126. Labrie, F., Dupont, A., Bélanger, A., Lacourcière, Y., Members of LUPCP. (1984) Complete androgen blockade at start of treatment causes a dramatic improvement of survival in advanced prostate cancer, in: Labrie, F., Bélanger, A. et Dupont, A., eds: Proceedings of the International Symposium on LHRH and its analogues: Basic and Clinical Aspects, Excerpta Medica, pp 368-379. Prostate Cancer 1984
125. Labrie, F., Dupont, A., Bélanger, A., Lacourcière, Y., Raynaud, J.P., Husson, J.M., Gareau, J., Fazekas, A.T.A., Sandow, J., Monfette, G. (1983) New approach in the treatment of prostate cancer: complete instead of only partial withdrawal of androgens. Prostate, 4: 579-594. Prostate Cancer 1983
124. Labrie, F., Dupont, A., Bélanger, A., Lefebvre, F.A., Cusan, L., Monfette, G., Laberge, J.G., Emond, J.P., Raynaud, J.P., Husson, J.M., Fazekas, A.T.A. (1983) New hormonal treatment in cancer of the prostate: combined administration of an LHRH agonist and an antiandrogen. J. Steroid Biochem., 19: 999-1007. Prostate Cancer 1983
123. Labrie, F., Dupont, A., Bélanger, A., Lefebvre, F.A., Cusan, L., Raynaud, J.P., Husson, J.M., Fazekas, A.T. (1983) New hormonal therapy in prostate cancer: combined use of a pure antiandrogen and an LHRH agonist. Horm. Res., 18: 18-27. Prostate Cancer 1983
122. Labrie, F., Dupont, A., Bélanger, A., Lefebvre, F.A., Raynaud, J.P. (1983) Nouvelle approche dans le traitement du cancer de la prostate: utilisation combinée d'un agoniste de la LHRH et d'un antiandrogène. J. Pharmacol. (Paris), 14 Suppl 3: 117-135. Prostate Cancer 1983
121. Labrie, F., Dupont, A., Bélanger, A., Members of LUPCP (1984) Spectacular response to combined antihormonal treatment in advanced prostate cancer, in: Labrie, F. et Proulx, L., eds: Endocrinology ICS 655, Excerpta Medica, pp 450-453. Prostate Cancer 1984
120. Labrie, F., Dupont, A., Bélanger, A., Poyet, P., Giguère, M., Lacourcière, Y., Emond, J., Monfette, G., Borsanyi, J.P. (1986) Combined treatment with Flutamide and surgical or medical (LHRH agonist) castration in metastatic prostatic cancer. Lancet, 327: 48-49. Prostate Cancer 1986
119. Labrie, F., Dupont, A., Bélanger, A., Simard, J., Labrie, C., Poulin, R., Luthy, I., Veilleux, R., Lacoste, D., Marchetti, B., Cusan, L., Manhès, G., Monfette, G., Emond, J. (1988) Combination therapy with the antiandrogen Flutamide and the LHRH agonist [D-Trp6,des-Gly-NH210]LHRH ethylamide in prostate cancer: rationale and 5-year clinical experience, in: Chretien, M. et McKerns, K.W., eds: Molecular Biology of Brain and Endocrine Peptidergic Systems, New York, Plenum Press, pp 83-101. Prostate Cancer 1988
118. Labrie, F., Dupont, A., Bélanger, A., St-Arnaud, R., Giguère, M., Lacourcière, Y., Emond, J., Monfette, G. (1986) Combined treatment with an LHRH agonist and the antiandrogen Flutamide in prostate cancer, in: Moody, T.W., ed. Neural Endocrine Peptides and Receptors, New York, Plenum Press, pp 627-644. Prostate Cancer 1986
117. Labrie, F., Dupont, A., Bélanger, A., St-Arnaud, R., Giguère, M., Lacourcière, Y., Emond, J., Monfette, G. (1986) Treatment of prostate cancer with gonadotropin-releasing hormone agonists. Endocrine Rev., 7: 67-74. Prostate Cancer 1986
116. Labrie, F., Dupont, A., Bélanger, A., St-Arnaud, R., Labrie, C., Members of LUPCP (1984) Medical castration with LHRH agonists and the need for combined treatment with an antiandrogen in prostate cancer, in: McKerns, K.W., ed. Hormonal Control of the Hypothalamic-Pituitary Gonadal Axis, New York, Plenum Press, pp 531-549. Prostate Cancer 1984
115. Labrie, F., Dupont, A., Cusan, L., Bélanger, A., Giguère, M., Labrie, C., Lacourcière, Y., Monfette, G., Emond, J. (1988) Combination therapy with Flutamide and [D-Trp6, des-Gly-NH210]LHRH ethylamide in stage C and D prostate cancer: Today's therapy of choice - Rationale and 5-year clinical experience. Prog. Clin. Biol. Res., 262: 11-63. Prostate Cancer 1988
114. Labrie, F., Dupont, A., Cusan, L., Giguère, M., Bergeron, N., Borsanyi, J.P., Lacourcière, Y., Bélanger, A., Emond, J., Monfette, G., Boucher, H., Lachance, R. (1988) Combination therapy with Flutamide and castration (LHRH agonist or orchiectomy) in previously untreated patients with clinical stage D2 prostate cancer: today's therapy of choice. J. Steroid Biochem., 30: 107-117. Prostate Cancer 1988
113. Labrie, F., Dupont, A., Cusan, L., Giguère, M., Bergeron, N., Lacourcière, Y., Bélanger, A., Monfette, G., Emond, J. (1988) Combination therapy with Flutamide and [D-Trp6]LHRH ethylamide in advanced (stages C and D) previously untreated prostate cancer, in: Motta, M. et Serio, M., eds: Hormonal therapy of prostatic diseases: basic and clinical aspects: International Symposium, Milano, Italy, April 6-8 1987: abstracts of lectures and free communications, pp 312-333. Prostate Cancer 1988
<< previous | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 next >>

Biography  |  Publications  |  Scientific Conferences  |  Selected Slide Presentations  |  Awards